Tasigna and Vitamin e drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Tasigna (nilotinib hydrochloride monohydrate) and Vitamin e (tocopherols and tocotrienols). Common drug interactions include fall among females and fatigue among males.

The phase IV clinical study analyzes what interactions people have when they take Tasigna and Vitamin e. It is created by eHealthMe based on reports of 30 people who take the same drugs from the FDA, and is updated regularly.

What is Tasigna?

Tasigna has active ingredients of nilotinib hydrochloride monohydrate. It is often used in chronic myelogenous leukemia (cml). eHealthMe is studying from 31,535 Tasigna users. Check the latest studies of Tasigna.

What is Vitamin e?

Vitamin e has active ingredients of tocopherols and tocotrienols. It is often used in vitamin supplementation. eHealthMe is studying from 42,279 Vitamin e users. Check the latest studies of Vitamin e.

On Jul, 13, 2026

30 people who take Tasigna and Vitamin e together, and have interactions are studied.

Tasigna and Vitamin e drug interactions.

What are the common drug interactions of Tasigna and Vitamin E, by gender? *:

female:

Fall
Heart rate irregular
Infection
Insomnia (sleeplessness)
Leukaemia (blood or bone marrow cancer)
Localised infection (infection at the single location)
Lung neoplasm malignant (cancer tumour of lung)
Night sweats (sweating in night)
Platelet count increased
Rhinorrhoea (watery mucus discharge from the nose)

male:

Fatigue (feeling of tiredness)
Acne (skin problems that cause pimples)
Gait disturbance
Hair disorder
Head discomfort
Hot flush (sudden feelings of heat)
Influenza
Malaise (a feeling of general discomfort or uneasiness)
Nausea (feeling of having an urge to vomit)
Obsessive-compulsive disorder (an anxiety disorder characterized by intrusive thoughts that produce uneasiness, apprehension, fear, or worry;)

What are the common drug interactions of Tasigna and Vitamin E, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Arteriovenous fistula
Contusion (a type of hematoma of tissue in which capillaries)
Dizziness
Fistula (an abnormal connection or passageway between two)
Haematocrit decreased
Haematoma (collection of blood outside the blood vessels)
Haemoglobin decreased
Haemorrhage (bleeding)
Malignant neoplasm progression (cancer tumour came back)
Mean cell haemoglobin decreased (less than normal haemoglobin per red blood cell in a sample of blood)

40-49:

n/a

50-59:

Anxiety
Arthralgia (joint pain)
Disease recurrence
Drug resistance (reduction in effectiveness of a drug)
Eye haemorrhage (bleeding in the eye)
Fatigue (feeling of tiredness)
Muscle spasms (muscle contraction)
Nausea (feeling of having an urge to vomit)
Platelet count increased
Rash

60+:

Fatigue (feeling of tiredness)
Rash
Fluid retention (an abnormal accumulation of fluid in the blood)
Gait disturbance
Hair disorder
Head discomfort
Hot flush (sudden feelings of heat)
Influenza
Malaise (a feeling of general discomfort or uneasiness)
Nausea (feeling of having an urge to vomit)

What are the existing conditions these people have? *

Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 21 people, 70.00%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 6.67%
Immunodeficiency Common Variable: 2 people, 6.67%
Hypopituitarism (diminished hormone secretion by the pituitary gland, causing dwarfism in children and premature aging in adults): 2 people, 6.67%
Gastric Disorder (disease of stomach): 2 people, 6.67%
Cardiac Disorder: 2 people, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Tasigna and Vitamin e?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously